Incyte partners with Edison Scientific to integrate AI across drug discovery and translational research.

{
  "signal_id": "ec65e1fb-272e-46f0-8507-7f1fa15a7c4a",
  "signal_type": "news",
  "signal_subtype": "integrates_with",
  "detected_at": "2026-05-22T13:44:37+00:00",
  "company": {
    "name": "Incyte",
    "domain": "incyte.com"
  },
  "data": {
    "url": "https://www.biopharminternational.com/view/incyte-partners-with-edison-scientific-to-integrate-ai-across-drug-discovery-and-translational-research",
    "title": "Incyte partners with Edison Scientific to integrate AI across drug discovery and translational research.",
    "ticker": "NASDAQ:INCY",
    "excerpt": "Incyte partners with Edison Scientific to integrate AI across drug discovery and translational research.\n\nIncyte and Edison Scientific have entered a strategic collaboration to integrate the Kosmos AI platform across Incyte's research and development operations, reflecting the growing role of continuous-learning AI systems in biopharmaceutical drug discovery and translational medicine.\n\nIncyte and Edison Scientific announced a strategic collaboration aimed at embedding artificial intelligence (AI) across the biopharmaceutical discovery and development process, with an initial focus on target discovery, validation, and translational biology.[1]\n\n\"Our vision is for our data to become a learning system that enhances every decision.\" - Pablo J. Cagnoni, MD, president and global head of research and development at Incyte\n\nUnder the agreement, Incyte will deploy Edison Scientific's Kosmos AI platform throughout its research and development workflows. The companies said the platform is designed to continuously learn from translational, biomarker, and clinical datasets to support experimental design, evidence synthesis, and predictive modeling of therapeutic performance.[1]\n\n\"Our vision is for our data to become a learning system that enhances every decision,\" said Pablo J. Cagnoni, MD, president and global head of research and development at Incyte, in the company announcement.[1]...",
    "summary": "Incyte Corporation integrates with Edison Scientific Inc..",
    "planning": false,
    "image_url": "https://cdn.sanity.io/images/0vv8moc6/biopharn/51df19fe271d3df2031737dfb61e9d01e5843860-1280x720.jpg",
    "confidence": 0.2476,
    "published_at": "2026-05-22T13:44:37Z",
    "article_sentence": "Incyte and Edison Scientific have entered a strategic collaboration to integrate the Kosmos AI platform across Incyte's research and development operations, reflecting the growing role of continuous-learning AI systems in biopharmaceutical drug discovery and translational medicine.",
    "related_company_name": "Edison Scientific Inc.",
    "related_company_domain": "edisonscientific.com"
  }
}

curl https://signals.autobound.ai/v1/signals/ec65e1fb-272e-46f0-8507-7f1fa15a7c4a \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"incyte.com","limit":20}'